尤瑞克林治疗急性大脑中动脉脑梗死的疗效观察  

Therapeutic effect of urinary kallidinogenase on acute middle cerebral artery infarction

作　　者：耿昌明[1] 朱雪红[1] 韦道明[1] 

机构地区：[1]解放军第85医院神经内科,上海200052

出　　处：《临床军医杂志》2010年第4期584-586,共3页Clinical Journal of Medical Officers

摘　　要：目的观察尤瑞克林治疗急性大脑中动脉脑梗死的近期临床疗效。方法 60例急性大脑中动脉脑梗死随机分成两组,两组均给予抗血小板聚集及一般常规用药,治疗组加用尤瑞克林(尤瑞克林0.15PNA+生理盐水100ml静滴,1次/d,连用7～10d)。于治疗前、治疗后第7天和第15天记录NIHSS评分。结果两组NIHSS评分与治疗前比较有显著改善(P<0.05);治疗组神经功能恢复明显优于对照组,NIHSS评分及临床总有效率比较差异均有统计学意义(P<0.05)。结论尤瑞克林治疗大脑中动脉脑梗死安全、有效。Objective To observe the clinical curative effect of urinary kallidinogenase on acute middle cerebral artery infarction and its safety.Methods Sixty acute middle cerebral artery infarction patients were randomly divided into trial group and control group.Both groups were given routine treatment.Urinary kallidinogenase was additionally given to the trial group.The degree of neurologic impairment of the two groups was observed and evaluated by NIHSS before and after treatment for 7 through 10 days.Results The nerve functional recovery of the trial group obviously surpassed that of the control group.There was statistical significance in total effective rate and NIHSS score between the two groups (P<0.05) .Conclusion Urinary kallidinogenase injection is effective in treating middle cerebral artery infarction.

关 键 词：急性大脑中动脉脑梗死 尤瑞克林 卒中量表 

分 类 号：R82[医药卫生—临床医学]